--- a
+++ b/clusters/3009knumclusters/clust_164.txt
@@ -0,0 +1,93 @@
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Have a known hypersensitivity or allergy to biopharmaceutical agents produced in Chinese hamster ovary cells or any component of the atezolizumab and/or bevacizumab formulations
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+History of hypersensitivity to Chinese hamster ovary (CHO) cells or other human or humanized recombinant antibodies.
+No known hypersensitivity to Chinese hamster ovary (CHO) cell products or any component of the atezolizumab formulation
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, fluoropyrimidines, folic acid derivatives or oxaliplatin
+Patients must not be known to be allergic to Chinese hamster egg or ovaries
+The patient must NOT have a known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Patients with known hypersensitivity to Chinese hamster ovary products or other recombinant human, chimeric, or humanized antibodies.
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells.
+Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells or any component of the atezolizumab formulation, or any component of the cobimetinib formulation
+Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
+Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells
+Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells or any component of the atezolizumab, cobimetinib, or vemurafenib formulations
+Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any components of cobimetinib, atezolizumab, or bevacizumab formulations
+Known hypersensitivity to Chinese hamster ovary (CHO) cell products or any component of the MPDL3280A formulation
+Known hypersensitivity to any of the components of cergutuzumab amunaleukin and atezolizumab; hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
+Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity allergy or contraindication to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the PD-1/PD-L1 inhibitor formulation;
+GENERAL: Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or to any component of the atezolizumab formulation
+Known hypersensitivity to Chinese hamster ovary cell products or recombinant human antibodies
+History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins or Chinese hamster ovary cell products.
+Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab or bevacizumab formulation
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Documented allergy or hypersensitivity to monoclonal antibodies (bevacizumab), to Chinese hamster ovarian cells of the or to any other humanized or recombinant antibodies
+Known hypersensitivity or allergy to Chinese hamster ovary cell products or any component of the MDPL3280A formulation
+Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or to any component of the atezolizumab formulation
+Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or other recombinant antibodies
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab or guadecitabine formulations
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to Chinese hamster ovary cell products or any of the study drugs
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
+This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
+Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation.
+Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
+Patients must not have known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation or known hypersensitivity to any component of cobimetinib or vemurafenib
+Known hypersensitivity to pharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
+Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells
+Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab, obinutuzumab, rituximab, or bendamustine formulation, including mannitol
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to Chinese hamster ovary cell products or any component of the atezolizumab formulation
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.
+History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins; known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
+Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
+Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cell or any component of the atezolizumab formulation
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Patients with known hypersensitivity of Chinese hamster ovary cell products, other recombinant human antibodies, or compounds of similar chemical or biologic composition to bevacizumab
+Known hypersensitivity to Chinese hamster ovary cell products or to recombinant human or murine antibodies, or any of the treatments in this protocol
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
+Known hypersensitivity to bevacizumab, Chinese hamster ovary cell products, or other recombinant human or humanized antibodies
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to any component of recombinant protein production by Chinese Hamster Ovary (CHO) cells
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity to any component of recombinant protein production by Chinese Hamster Ovary (CHO) cells
+Prior hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies (Phase I and II)
+Phase 1b and crossover only: History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins; Known hypersensitivity to Chinese Hamster Ovary (CHO)-cell products; Allergy or hypersensitivity to components of the atezolizumab formulation
+Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, and patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in the study
+Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies including hypersensitivity to any component of bevacizumab
+Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation, emactuzumab formulation, or obinutuzumab formulation
+Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or other recombinant human antibodies
+Have at least one ovary
+Patient must not have a known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
+Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
+Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation